# CXC Chemokine‐Driven Vascular Reprogramming: Modulating Tumor Vasculature to Boost Therapeutic Response

**Authors:** Hongdan Chen, Yinde Huang, Juntong Wu, Ziying Yi, Yao Li, Zeyu Yang, Fan Zhang, Chong Li

PMC · DOI: 10.1002/advs.202523331 · Advanced Science · 2026-01-20

## TL;DR

This paper explores how CXC chemokines regulate tumor blood vessels and immune access, offering new tools to improve cancer therapy.

## Contribution

The paper introduces a chemokine-centered framework for vascular normalization, including a functional vascular normalization score and targeted strategies.

## Key findings

- CXC chemokines dynamically regulate vascular function through bidirectional, temporal, and tissue-specific mechanisms.
- A functional vascular normalization score (FVNS) is proposed to guide real-time vascular assessment and treatment strategies.
- CXC-targeted approaches like CXCR2/CXCR4 blockade and CXCL9/10/11 augmentation may enhance vascular and immune therapies.

## Abstract

Aberrant tumor vasculature drives hypoxia, immune exclusion, and therapeutic resistance. However, current vascular normalization strategies remain primarily VEGF‐centered, relying on morphological and perfusion metrics with limited molecular readouts to monitor vessel function. This highlights the need for alternative frameworks to identify therapeutic windows and enhance vascular‐immune strategies. Here, we introduce a chemokine‐centered perspective that positions the CXC chemokine network as a dynamic regulator of vascular functionality. We highlight three core mechanistic dimensions: bidirectionality, temporal dynamics, and tissue specificity, and further emphasize the functional synergy emerging from their network‐level interactions. Building on these features, we propose the functional vascular normalization score (FVNS) and the chemokine‐guided vascular normalization window (VNW) as molecular tools for real‐time vascular assessment and therapeutic stratification. Finally, we outline CXC‐targeted strategies, including CXCR2/CXCR4 blockade, CXCL9/10/11 augmentation, and spatiotemporally controlled delivery platforms, which may extend and personalize the VNW. This chemokine‐focused paradigm provides a functional and implementable approach for the integration of vascular normalization and immune modulation in cancer therapy.

Tumor vascular remodeling is discussed from a chemokine‐centered perspective. This review summarizes the bidirectional, temporal, and tissue‐specific roles of CXC chemokines in regulating vascular function and immune accessibility. A functional vascular normalization score is introduced as a conceptual framework to integrate dynamic vascular and immune states, informing therapeutic stratification and combination strategies.

## Linked entities

- **Proteins:** CXCR2 (C-X-C motif chemokine receptor 2), CXCR4 (C-X-C motif chemokine receptor 4), CXCL9 (C-X-C motif chemokine ligand 9), CXCL10 (C-X-C motif chemokine ligand 10), CXCL11 (C-X-C motif chemokine ligand 11)
- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, CXCR2 (C-X-C motif chemokine receptor 2) [NCBI Gene 3579] {aka CD182, CDw128b, CMKAR2, IL8R2, IL8RA, IL8RB}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** Tumor (MESH:D009369), hypoxia (MESH:D000860)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12931211/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12931211/full.md

## References

155 references — full list in the complete paper: https://tomesphere.com/paper/PMC12931211/full.md

---
Source: https://tomesphere.com/paper/PMC12931211